6748
document
Famotidine treatment of children with autistic spectrum disorders : pilot research using single subject research design . Using single subject research design , we performed pilot research to evaluate the safety and efficacy of famotidine for the treatment of children with autistic spectrum disorders . We studied 9 Caucasian boys , 3.8-8.1 years old , with a DSM-IV diagnosis of a pervasive developmental disorder , living with their families , receiving no chronic medications , and without significant gastrointestinal symptoms . The dose of oral famotidine was 2 mg/kg/day ( given in two divided doses ) ; the maximum total daily dose was 100 mg . Using single-subject research analysis and medication given in a randomized , double-blind , placebo-controlled , cross-over design , 4 of 9 children randomized ( 44 % ) had evidence of behavioral improvement . Primary efficacy was based on data kept by primary caregivers , including a daily diary ; daily visual analogue scales of affection , reciting , or aspects of social interaction ; Aberrant Behavior Checklists ( ABC , Aman ) ; and Clinical Global Improvement scales . Children with marked stereotypy ( meaningless , repetitive behaviors ) did not respond . Our subjects did not have prominent gastrointestinal symptoms and endoscopy was not part of our protocol ; thus , we can not exclude the possibility that our subjects improved due to the effective treatment of asymptomatic esophagitis . The use of famotidine for the treatment of children with autistic spectrum disorders warrants further investigation .
6749
Intervention_Pharmacological
Famotidine
6750
Intervention_Pharmacological
famotidine
6751
Intervention_Pharmacological
oral famotidine was 2 mg/kg/day ( given in two divided doses ) ; the maximum total daily dose was 100 mg .
6752
Intervention_Pharmacological
famotidine
6753
Outcome_Mental
behavioral improvement
6754
Outcome_Physical
daily diary ; daily visual analogue scales of affection , reciting , or aspects of social interaction
6755
Outcome_Physical
Aberrant Behavior Checklists ( ABC , Aman )
6756
Outcome_Physical
Clinical Global Improvement scales
6757
Outcome_Physical
gastrointestinal symptoms
6758
Participant_Condition
autistic spectrum disorders
6759
Participant_Condition
autistic spectrum disorders
6760
Participant_Sample-size
9 Caucasian
6761
Participant_Age
3.8-8.1 years
6762
Participant_Condition
DSM-IV diagnosis of a pervasive developmental disorder